Correlation Between Amicus Therapeutics and Eliem Therapeutics
Can any of the company-specific risk be diversified away by investing in both Amicus Therapeutics and Eliem Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Amicus Therapeutics and Eliem Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Amicus Therapeutics and Eliem Therapeutics, you can compare the effects of market volatilities on Amicus Therapeutics and Eliem Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Amicus Therapeutics with a short position of Eliem Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Amicus Therapeutics and Eliem Therapeutics.
Diversification Opportunities for Amicus Therapeutics and Eliem Therapeutics
0.41 | Correlation Coefficient |
Very weak diversification
The 3 months correlation between Amicus and Eliem is 0.41. Overlapping area represents the amount of risk that can be diversified away by holding Amicus Therapeutics and Eliem Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Eliem Therapeutics and Amicus Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Amicus Therapeutics are associated (or correlated) with Eliem Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Eliem Therapeutics has no effect on the direction of Amicus Therapeutics i.e., Amicus Therapeutics and Eliem Therapeutics go up and down completely randomly.
Pair Corralation between Amicus Therapeutics and Eliem Therapeutics
Given the investment horizon of 90 days Amicus Therapeutics is expected to under-perform the Eliem Therapeutics. But the stock apears to be less risky and, when comparing its historical volatility, Amicus Therapeutics is 3.05 times less risky than Eliem Therapeutics. The stock trades about -0.05 of its potential returns per unit of risk. The Eliem Therapeutics is currently generating about 0.04 of returns per unit of risk over similar time horizon. If you would invest 270.00 in Eliem Therapeutics on August 25, 2024 and sell it today you would earn a total of 30.00 from holding Eliem Therapeutics or generate 11.11% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Together |
| Strength | Weak |
| Accuracy | 99.56% |
| Values | Daily Returns |
Amicus Therapeutics vs. Eliem Therapeutics
Performance |
| Timeline |
| Amicus Therapeutics |
| Eliem Therapeutics |
Amicus Therapeutics and Eliem Therapeutics Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Amicus Therapeutics and Eliem Therapeutics
The main advantage of trading using opposite Amicus Therapeutics and Eliem Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Amicus Therapeutics position performs unexpectedly, Eliem Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Eliem Therapeutics will offset losses from the drop in Eliem Therapeutics' long position.| Amicus Therapeutics vs. Eliem Therapeutics | Amicus Therapeutics vs. HCW Biologics | Amicus Therapeutics vs. Scpharmaceuticals | Amicus Therapeutics vs. Milestone Pharmaceuticals |
| Eliem Therapeutics vs. Pmv Pharmaceuticals | Eliem Therapeutics vs. MediciNova | Eliem Therapeutics vs. Pharvaris BV | Eliem Therapeutics vs. PepGen |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Other Complementary Tools
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities |